Immunogenicity and In Vivo Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein-1 in Aotus Monkeys

Abstract

Vaccination of A. nancymai with yMSP1(19) induced protective immune responses. The course of recrudescing parasitemias in protected monkeys suggested that immunity is not mediated by antibodies that block invasion. Our data indicate that vaccine trials with the highly adapted FVO strain of P. falciparum can be tested in A. nancymai and that MSP1(19) is a promising anti-blood-stage vaccine for human trials.

Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite.

“…[7][8][9][10][11] A small number of heterologous challenges have been performed in the past using P. falciparum strains in Aotus monkeys. These studies, performed in other species of Aotus, also showed that previous infection provided protection from subsequent challenge with the same strain.…”

Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development

“…[36][37][38] Several other molecules are being channelled into human trials on the basis of results considered promising and obtained in one of the primate, mouse, or in-vitro models (figure 1). [39][40][41][42][43] Clinical trials will be essential to show whether these results can be extended to human beings.…”

Different Plasmodium falciparum Recombinant MSP119 Antigens Differ in Their Capacities to Stimulate In Vitro Peripheral Blood T Lymphocytes in Individuals from Various Endemic Areas

“…Parts of MSP1, and in particular the C-terminal region have been produced in various expression systems [7]. Immunization of nonhuman primates using various preparations of recombinant MSP1 19 and MSP1 42 led to inconsistent results in terms of protection against a live-parasite challenge ( [7][8][9][10][11] Kaslow et al, unpublished data; Longacre et al, unpublished data).…”